These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 36792313)
1. Acute pain service reduces barriers to buprenorphine/naloxone initiation by using regional anesthesia techniques. Seol A; Chan J; Micham B; Ye Y; Mariano ER; Harrison TK; Hunter OO Reg Anesth Pain Med; 2023 Aug; 48(8):425-427. PubMed ID: 36792313 [TBL] [Abstract][Full Text] [Related]
2. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097 [TBL] [Abstract][Full Text] [Related]
3. Successful rotation from long-acting full agonist opioids to sublingual buprenorphine/naloxone using a microdosing approach. Vytialingam RC; Schug SA; O'Regan R J Opioid Manag; 2021; 17(7):159-166. PubMed ID: 34520037 [TBL] [Abstract][Full Text] [Related]
4. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter. Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641 [No Abstract] [Full Text] [Related]
5. Acute pain control challenges with buprenorphine/naloxone therapy in a patient with compartment syndrome secondary to McArdle's disease: a case report and review. McCormick Z; Chu SK; Chang-Chien GC; Joseph P Pain Med; 2013 Aug; 14(8):1187-91. PubMed ID: 23647815 [TBL] [Abstract][Full Text] [Related]
7. The problem of pain: Additive analgesic effect of tramadol and buprenorphine in a patient with opioid use disorder. Montalvo C; Genovese N; Renner J Subst Abus; 2019; 40(2):136-139. PubMed ID: 30835647 [No Abstract] [Full Text] [Related]
8. Successful use of buprenorphine-naloxone medication-assisted program to treat concurrent pain and opioid addiction after cancer therapy. Moryl N; Filkins A; Griffo Y; Malhotra V; Jain RH; Frierson E; Inturrisi C J Opioid Manag; 2020; 16(2):111-118. PubMed ID: 32329886 [TBL] [Abstract][Full Text] [Related]
9. Opioid drug utilization and cost outcomes associated with the use of buprenorphine-naloxone in patients with a history of prescription opioid use. Kaur AD; McQueen A; Jan S J Manag Care Pharm; 2008 Mar; 14(2):186-94. PubMed ID: 18331120 [TBL] [Abstract][Full Text] [Related]
10. The Naloxone Component of Buprenorphine/Naloxone: Discouraging Misuse, but at What Cost? Gregg J; Hartley J; Lawrence D; Risser A; Blazes C J Addict Med; 2023 Jan-Feb 01; 17(1):7-9. PubMed ID: 35913990 [TBL] [Abstract][Full Text] [Related]
11. Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: secondary analysis of a Canadian treatment trial. Socias ME; Wood E; Le Foll B; Lim R; Choi JC; Mok WY; Bruneau J; Rehm J; Wild TC; Bozinoff N; Hassan A; Jutras-Aswad D; Addiction; 2022 Oct; 117(10):2662-2672. PubMed ID: 35712892 [TBL] [Abstract][Full Text] [Related]
12. Patient opinion and acceptance of emergency department buprenorphine/naloxone to-go home initiation packs. Duncan K; Scheuermeyer F; Lane D; Ahamad K; Moe J; Dong K; Nolan S; Buxton J; Miles I; Johnson C; Christenson J; Whyte M; Daoust R; Garrod E; Badke K; Kestler A CJEM; 2023 Oct; 25(10):802-807. PubMed ID: 37606738 [TBL] [Abstract][Full Text] [Related]
13. Buprenorphine/naloxone initiation and referral as a quality improvement intervention for patients who live with opioid use disorder: quantitative evaluation of provincial spread to 107 rural and urban Alberta emergency departments. Stone KD; Scott K; Holroyd BR; Lang E; Yee K; Taghizadeh N; Deol J; Dong K; Fanaeian J; Ghosh M; Low K; Ross M; Tanguay R; Faris P; Day N; McLane P CJEM; 2023 Jul; 25(7):598-607. PubMed ID: 37245202 [TBL] [Abstract][Full Text] [Related]
14. A Descriptive analysis of urine drug screen results in patients with opioid use disorder managed in a primary care setting. Sobel HG; Warrington JS; Francis-Fath S; Crocker AM; Berger CA Addict Sci Clin Pract; 2021 Sep; 16(1):59. PubMed ID: 34593036 [TBL] [Abstract][Full Text] [Related]
15. Statewide Availability of Buprenorphine/Naloxone in Acute Care Hospitals. Pham S; Haigh A; Barrett E J Addict Med; 2022 Jan-Feb 01; 16(1):e48-e51. PubMed ID: 33758118 [TBL] [Abstract][Full Text] [Related]
16. Case of buprenorphine-associated central sleep apnea resolving with dose reduction. Tchikrizov V; Richert AC; Bhardwaj SB J Opioid Manag; 2022; 18(4):391-394. PubMed ID: 36052936 [TBL] [Abstract][Full Text] [Related]
17. Flexible Buprenorphine/Naloxone Treatment Models: Safe and Effective in Reducing Opioid Use Among Persons With Prescription Opioid Use Disorder. Saunders EC Am J Psychiatry; 2022 Oct; 179(10):699-701. PubMed ID: 36181331 [No Abstract] [Full Text] [Related]
18. Rapid Micro-induction of Buprenorphine/Naloxone for Opioid Use Disorder in a Critically ill Intubated Patient: A Case Report. Hamata B; Griesdale D; Hann J; Rezazadeh-Azar P J Addict Med; 2020 Dec; 14(6):514-517. PubMed ID: 32649330 [TBL] [Abstract][Full Text] [Related]
19. Acute pain management in opioid-tolerant patients: a growing challenge. Huxtable CA; Roberts LJ; Somogyi AA; MacIntyre PE Anaesth Intensive Care; 2011 Sep; 39(5):804-23. PubMed ID: 21970125 [TBL] [Abstract][Full Text] [Related]
20. Buprenorphine/naloxone versus methadone opioid rotation in patients with prescription opioid use disorder and chronic pain: study protocol for a randomized controlled trial. Ellerbroek H; van den Heuvel SAS; Dahan A; Timmerman H; Kramers C; Schellekens AFA Addict Sci Clin Pract; 2022 Sep; 17(1):47. PubMed ID: 36057608 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]